Safety and Efficacy of Ivabradine Hydrochloride in Hemodialysis Patients with Chronic Heart Failure
- Conditions
- Hemodialysis patients with chronic heart failure whose resting heart rate is 75 beats per minute or higher
- Registration Number
- JPRN-UMIN000045871
- Lead Sponsor
- ippon Medical School
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Not provided
1. patients with a history of hypersensitivity to any component of ivabradine hydrochloride 2. patients with unstable or acute heart failure 3. patients with cardiogenic shock 4. patients with severe hypotension (systolic blood pressure less than 90 mmHg or diastolic blood pressure less than 50 mmHg) 5. patients with atrial fibrillation 6. patients with sinus failure syndrome, sinoatrial block, or third degree atrioventricular block 7. patients with severe hepatic dysfunction 7) Patients with severe hepatic dysfunction (Child-Pugh C) 8. patients receiving the following drugs: ritonavir-containing products, josamycin, itraconazole, clarithromycin, cobicistat-containing products, indinavir, voriconazole, nelfinavir, saquinavir, telaprevir 9. patients who are pregnant, lactating, may be pregnant or plan to become pregnant 10. patients who are receiving verapamil or diltiazem 11. patients who are scheduled to undergo surgical treatment during the study period 12. 12. patients who require a substitute.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in resting heart rate from baseline to 12 weeks post-dose
- Secondary Outcome Measures
Name Time Method